BNP Paribas Financial Markets
RANI icon

BNP Paribas Financial Markets’s Rani Therapeutics RANI Stock Holding History

BNP Paribas Financial Markets’s Portfolio RANI Stock Details RANI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.13K Sell
1,543
-73
-5% -$93 ﹤0.01% 5464
2025
Q4 		$2.18K Buy
+1,616
New +$2.44K ﹤0.01% 5342
2022
Q4 		– Sell
-151
Closed -$1.45K – 4487
2022
Q3 		$1.45K Buy
+151
New +$1.6K ﹤0.01% 4384

Other funds holding RANI

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SCP
SymBiosis Capital Partners Bentonville, Arkansas $52.8M AUM
LP
Longaeva Partners Chicago, Illinois $2.7B AUM 37.16% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NFGH
Nan Fung Group Holdings Kai Tak, Hong Kong $121M AUM 56.89% 1-Year Est. Return

BNP Paribas Financial Markets's RANI Position: Q1 2026 in Review

BNP Paribas Financial Markets reduced its Rani Therapeutics (RANI) stake by 4.5% in Q1 2026, selling an estimated $93 and leaving 1,543 shares worth $1.13K. The position accounts for ﹤0.01% of the portfolio, ranked #5464.

BNP Paribas Financial Markets first reported a position in RANI in Q3 2022 and has held it in 3 quarters since. The position peaked at $2.18K in Q4 2025. 74 funds tracked by Wall St. Rank hold RANI as of Q1 2026.

  • BNP Paribas Financial Markets held 1,543 shares of Rani Therapeutics worth $1.13K as of Q1 2026.
  • BNP Paribas Financial Markets sold 73 Rani Therapeutics shares in Q1 2026, an estimated $93.
  • Rani Therapeutics made up ﹤0.01% of BNP Paribas Financial Markets's portfolio in Q1 2026, its #5464 holding.
  • BNP Paribas Financial Markets first reported a position in Rani Therapeutics in Q3 2022 and has held it in 3 quarters since.
  • BNP Paribas Financial Markets's Rani Therapeutics position peaked at $2.18K in Q4 2025.
  • 74 funds tracked by Wall St. Rank held Rani Therapeutics as of Q1 2026.

Based on BNP Paribas Financial Markets's 13F filing for Q1 2026, filed 12 May 2026.